• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Andrew Left Says Trump and Clinton Agree on Just One Thing

Attacking Big Pharma price gougers may be all that unifies the candidates ahead of tonight's debate.
By JAMES PASSERI Sep 26, 2016 | 01:30 PM EDT
Stocks quotes in this article: VRX, MYL, MNK, TEVA

It would seem obvious that Valeant Pharmaceuticals (VRX) CEO Joseph Papa would prefer to see anyone seated in the Oval Office next January other than one of his firm's most vociferous critics, Hillary Clinton.

After all, Clinton has said in a video earlier this year that she's "going after" the struggling Canadian drugmaker for "predatory pricing" on several of its acquired drugs -- a Valeant practice that's stirred controversy and contributed to shares falling about 74% this year alone.  

But a Trump presidency would be no walk in the park for the debt-laden drugmaker either -- especially given Valeant's heavy reliance on Medicare payouts and disproportionate U.S. footprint.

"Regulating the price of pharmaceuticals and eliminating price gouging might be the only issue that Trump and Hillary both agree on," Andrew Left, the short-seller who was instrumental in exposing accounting improprieties at Valeant last fall, said in a Monday phone interview with Real Money. Left is the head of Citron Research, which labeled Valeant a "pharmaceutical Enron" last fall based on accounting improprieties tied to Valeant's former partnership with mail-order pharmacy Philidor.

Valeant shares were skidding more than 5% in midday trading ahead of Monday's debate between the two candidates (the first of three this season). Pharma investors are bracing for a showdown that could dedicate substantial time to the widespread price-hiking among Big Pharma giants, most recently kindled by Mylan (MYL) in the exorbitant price increases on its life-saving EpiPen allergy treatment.

"What we see with Mylan post-Valeant, is that this is not going away fast," Left added. "I think that people understand the fact that this is not over."

TD Securities analysts appear to agree, releasing estimates Monday that Valeant is disproportionately reliant on Medicare payments and the U.S. pharmaceutical industry vs. many of its peers. TD Securities estimates that 63% of Valeant's sales come domestically and that 20% are tied to Medicare, a government program both presidential candidates have blasted for stifling competition.

About 2% of Valeant's sales are also likely to disappear if programs such as Clinton's "Drug Pricing Reform Proposal" are affected, TD Securities analysts Lennox Gibbs estimates, noting that both candidates are in favor of "price watchdog committees" that could further encumber Valeant's pricing power in the U.S.

Shares of Valeant and industry peers such as Mallinckrodt (MNK) and Teva Pharmaceuticals (TEVA) , which were down about 5% and 2%, respectively, ahead of the debates, were also pressured Monday by reports that Mylan may be booking pretax profits tied to its EpiPen that are about 60% of what was presented to a recent congressional panel centered on EpiPen price hikes. 

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

TAGS: Investing | U.S. Equity | Regulation | Markets | Healthcare | Drug Approvals | Politics | Stocks | Agriculture

More from Healthcare

2 Biotech Stocks to Own as M&A Potentially Gathers Steam

Bret Jensen
May 11, 2022 11:35 AM EDT

I like these names as stand-alone entities but they should also attract interest from larger players.

China Faces 'Tsunami' of Covid Infection That Could Swamp the System

Alex Frew McMillan
May 11, 2022 9:00 AM EDT

A new study suggests 1.55 million people could die if China abandons zero-Covid, with the intensive-care system needing 15.6 times existing capacity.

I'm Giving Dynavax Another Shot -- a Booster Shot

Bret Jensen
May 8, 2022 7:31 AM EDT

Despite an earnings miss, DVAX show promise in several vaccine fronts and I'm doubling down on the name.

In This Environment, I'd Be More Risk Averse With Intuitive Surgical

Stephen Guilfoyle
Apr 25, 2022 10:50 AM EDT

The firm has been hurt and continues to be hurt by the effects of the pandemic.

CVS Stock Needs to Refill Its Prescription

Bruce Kamich
Mar 29, 2022 12:01 PM EDT

Charts are looking 'toppy' right now.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 10:10 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    "Market Timing for Dummies"
  • 01:44 PM EDT STEPHEN GUILFOYLE

    Stocks Under $10 Portfolio

    We're making a series of trades here.
  • 03:07 PM EDT PAUL PRICE

    Why Is Walmart Down Big Today?

    Besides its poor earnings report Walmart was way...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login